What caused the CYBN.NE stock drop on 06 Mar 2026?

The drop followed a gap down from **C$10.59** to **C$7.40**, with market focus on potential listing concerns and sector-wide weakness in psychedelic biotech. Volume was normal, suggesting targeted selling rather than broad illiquidity.

What is Meyka AI’s forecast for CYBN.NE stock?

Meyka AI's forecast model projects **C$7.87** (monthly) and **C$8.01** (quarterly) for CYBN.NE. These imply short-term upside of about **6–8%** versus **C$7.40**, and are model projections, not guarantees.

What are key technical levels for CYBN.NE stock traders?

Immediate support is the year low **C$6.95** and resistance at the 50-day average **C$9.28** and prior close **C$10.59**. RSI **39.81** and CCI **-153.48** show oversold conditions.

How does Cybin’s valuation compare to the Healthcare sector?

Cybin’s price-to-book near **1.32** is below the healthcare sector average **~2.43**, but negative EPS (**-5.17**) and negative cash flow mean traditional multiples are less informative.

CA Stocks

Cybin Inc. (CYBN.NE NEO) down 30.12% on 06 Mar 2026: key support ahead

ByDanny Kontos March 7, 2026

CYBN.NE stock plunged 30.12% to C$7.40 on 06 Mar 2026 during market hours on the NEO exchange in Canada. The drop followed a gap down from a previous close of C$10.59, with an intraday low of C$7.30 and volume of 19,396 shares. Cybin Inc. (CYBN.NE) now trades below its 50-day average of C$9.28 and 200-day average of C$9.60, leaving near-term support at the year low of C$6.95. This article breaks down the drivers, valuation, technical levels and model forecasts for traders watching top losers today.